Page 333 - 2022_01-Haematologica-web

Letters to the Editor
South Wales, Australia; 7Icon Cancer Center, Brisbane, Queensland, Australia; 8Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia; 9Nanix Ltd., Dunedin, New Zealand; 10Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand; 11Materials Characterization and Fabrication Platform, Department of Chemical Engineering, University of Melbourne, Melbourne, Victoria, Australia; 12Department of Epidemiology and Preventive Medicine, Alfred Health – Monash University, Melbourne, Victoria, Australia and 13Faculty of Medicine, University of Melbourne, St Vincent’s Hospital Melbourne, Melbourne, Vitoria, Australia (on behalf of The Australasian Leukemia and Lymphoma Group [ALLG])
Correspondence:
ANDREW SPENCER - Andrew.spencer@monash.edu doi:10.3324/haematol.2021.278655
Received: February 24, 2021.
Accepted: September 21, 2021.
Pre-published: September 30, 2021.
Disclosures: AK received honoraria from Amgen, Celgene/BMS, Pfizer, Janssen and Roche. CSL received honoraria from Sandoz. AS consults for Takeda, Secura Bio, Servier, Clegene, Amgen, Abbvie, Specialized Therapeutics Australia; received honoraria from Servier, Celgene, Amgen, Abbvie, Specialized Therapeutics Australia, is part of the Speakers Bureau of Takeka, Jansen and Celgene; received research funding from Celgene and Amgen. HQ consults for Amgen, Celgene, Sanofi Genzyme, and Jansen; received research funding from Amgen, Celgene and Sanofi Genzyme; is part of the scientific steering committee of Amgen, Karyopharm and GSK. JDR sits on the advisory board of Celgene and Abbvie; received honoraria from Celgene and Abbvie. JE sits on the advisory board of Janssen and Celgene. JR received honoraria from Novartis Australia, is employed by Alfred Health; acts as a biostatistician for trials funded by the Australian government and Abbvie, Amgen, Celgene, GSK, Janssen-Cilag, Merck, Novartis, Takeda, but sponsored by Alfred Health.; consults for the Australasian Leukemia & Lymphoma Group (ALLG); owns equi- ty of Novartis AG. PM sits on the advisory board of Janssen, BMS/Celgene, Amgen, Takeka, Pfizer and Caelum (no personal fees received from any of them); received research funding from Janssen. All other authors have no conflicts of interest to disclose.
Contributions: AS conceived the study; AK and AS designed the work that led to the submission; AK, PJH, PM, JDR, KT, JE, HQ and NK were involved in the conduct of the study; AK, TK, MR, AM performed experiments/acquired data; AK, AS, JR, SN, RK analyzed/interpreted the data; AK wrote the manuscript; AS, AK and SN drafted the manuscript. All authors reviewed and provided revisions for the manuscript, approved the final version and agreed to be accountable for all aspects of the work in ensuring that ques- tions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Acknowledgements: We would like to thank all the patients and their families for participating in the study and our colleagues at participating hospitals who contributed to the study.
Funding: this work was supported by grants from Celgene Corporation and The Merrin Foundation.
References
1. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunother- apy in multiple myeloma. Br J Haematol. 2007;138(5):563-579.
2. Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013;122(14):2305- 2309.
3.Sehgal K, Das R, Zhang L, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042- 4051.
4. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155-167.
5. Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells in mul- tiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9(1):116.
6. de Vries NL, van Unen V, Ijsselsteijn ME, et al. High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. Gut. 2020;69(4):691-703.
7. Samusik N, Good Z, Spitzer MH, Davis KL, Nolan GP. Automated mapping of phenotype space with single-cell data. Nat Methods. 2016;13(6):493-496.
8. Norton SE, Leman JKH, Khong T, et al. Brick plots: an intuitive plat- form for visualizing multiparametric immunophenotyped cell clus- ters. BMC Bioinformatics. 2020;21(1):145.
9. Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Anti-myeloma activity of natural killer lymphocytes. Br J Hameatol. 2002;119(3):660-664.
10.Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7(10):e47077.
11. Hadjiaggelidou C, Mandala E, Terpos E, et al. Evaluation of regula- tory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: cor- relations with treatment outcome. Ann Hematol. 2019;98(6):1457- 1466.
12. Quach H, Ritchie D, Neeson P, et al. Regulatory T cells (Treg) are depressed in patients with relapsed/refractory multiple myeloma (MM) and increases towards normal range in responding patients treated with lenalidomide (LEN). Blood. 2008;112(11):1696-1696.
13. Joshua D, Suen H, Brown R, et al. The T cell in myeloma. Clin Lymphoma Myeloma Leuk. 2016;16(10):537-542.
14. Singel KL, Segal BH. Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol Rev. 2016;273(1):329-343.
15. Romano A, Parrinello NL, Simeon V, et al. High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune- suppressive due to increased STAT3 downstream signaling. Sci Rep. 2020;10(1):1983.
haematologica | 2022; 107(1)
325